To understand the pharmacological action and clinical application of ulinastatin, and to provide reference for clinical rational drug use.
Methods: The pharmacology and clinical application of ulinastatin were reviewed in recent years.
Results and conclusion: Ulinastatin in the treatment of pancreatitis can effectively reduce the necrosis and edema of pancreas and inhibit the inflammatory response of the body, which is of great value in the treatment of pancreatitis. In the treatment of sepsis, the injury of tissues and organs can be alleviated, the apoptosis of spleen cells can be inhibited, and the overall survival rate of sepsis patients can be improved. The microcirculation of tissues and organs can be improved in the treatment of shock, which is helpful to control the continuous development of shock state. In the treatment of ischemia-reperfusion injury, the release of oxygen free radicals and calcium influx can be reduced, the balance of calcium ions can be adjusted, the excitatory amino acid release and accumulation caused by calcium overload can be blocked, and organ protection can be played by increasing the concentration of nitric oxide and the activity of hydrolase. In the treatment of cardiopulmonary and brain resuscitation, it can reduce the level of proinflammatory factors in serum and achieve cerebral protection. In the treatment of lung injury, it can play a protective role by inhibiting the related factors of inflammation initiation. In the treatment of liver diseases, it can improve the related liver function indicators and coagulation function of mild/moderate patients, shorten the hospitalization period, but has no obvious therapeutic effect on severe patients. The levels of creatine kinase isoenzyme and cardiac troponin can be significantly reduced in patients undergoing cardiopulmonary bypass, which has a protective effect on other tissues and organs.